NVET

NEXVET BIOPHARMA PLC Stock Price

6.72
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
6.72
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Nexvet Biopharma Plc - Ordinary Shares NVET NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 6.72 19:00:00
Open Price Low Price High Price Close Price Prev Close
6.72 6.72
Bid Price Ask Price Spread News
6.00 7.90 1.90 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 6.72 USD

NEXVET BIOPHARMA PLC Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 79.25M 11.79M 11.79M $ - $ - -1.68 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

NEXVET BIOPHARMA PLC News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NVET Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

NEXVET BIOPHARMA PLC Description

Nexvet Biopharma PLC was incorporated in Ireland in August 2014 as Nexvet Biopharma Limited a private limited company. The Company then re-registered as a public limited company known as Nexvet Biopharma public limited company in September 2014. The Company is a clinical-stage biopharmaceutical company. The Company along with its subsidiaries is engaged in transforming the therapeutic market for companion animals by developing and commercializing novel, species-specific biologics based on human biologics. The Company's proprietary platform including PETization an algorithmic approach that enables to rapidly create monoclonal antibodies that are designed to be recognized as self or native by an animal's immune system. It is also designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals.


Your Recent History
NASDAQ
NVET
NEXVET BIO..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.